West Virginia House Bill HB 4197

West Virginia 2026 Regular Session

• Introduced: 1/14/26
• Refer: 1/14/26

Caption

Mandating health insurance coverage treatment of pediatric patients diagnoced with PANDAS or PANS

Summary

HB 4197 would require health insurance coverage for treatment of pediatric patients diagnosed with PANDAS or PANS. Based on the bill caption, the measure is aimed at ensuring that children diagnosed with these conditions have insurance access to medically necessary diagnosis and treatment services. The bill text itself was not available in the provided materials, so the precise scope of mandated benefits, exclusions, and implementation details cannot be confirmed from the record provided. As described, the bill would likely affect state insurance law by adding a coverage mandate for private health plans regulated by West Virginia, potentially requiring insurers to cover evaluation, treatment, and related care for affected pediatric patients. It would primarily impact health insurers, policyholders, pediatric patients, and healthcare providers who diagnose and treat PANDAS/PANS. The bill was referred to the House Health and Human Resources Committee on January 14, 2026, indicating it was in early committee consideration at the time reflected in the record.

Impact

HB 4197 would likely amend West Virginia insurance requirements by creating a new mandated benefit for pediatric PANDAS/PANS treatment, affecting the scope of covered services under state-regulated health plans. The practical impact would fall on insurers, employers offering health coverage, families of affected children, and clinicians providing diagnosis and treatment, though the exact statutory changes cannot be determined without the bill text.

Sentiment

No committee transcript or vote record was provided, so there is no direct evidence of debate, support, or opposition in the materials supplied. The bill’s caption suggests a health-coverage expansion intended to address a pediatric medical need, which typically indicates a supportive policy rationale, but the available record does not show whether lawmakers or stakeholders raised concerns about cost, medical necessity, or coverage standards.

Contention

Because no discussion transcript or vote history was included, specific points of contention are not documented in the provided materials. In bills of this type, likely areas of dispute would include whether PANDAS/PANS should be treated as a covered condition, how treatment would be defined, whether coverage mandates would increase premiums, and whether insurers should be required to cover therapies that may be viewed as experimental or not uniformly accepted. However, these concerns are inferred generally and are not attributed to any named participant in the record.